AR041079A1 - Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma) - Google Patents
Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma)Info
- Publication number
- AR041079A1 AR041079A1 ARP030103120A ARP030103120A AR041079A1 AR 041079 A1 AR041079 A1 AR 041079A1 AR P030103120 A ARP030103120 A AR P030103120A AR P030103120 A ARP030103120 A AR P030103120A AR 041079 A1 AR041079 A1 AR 041079A1
- Authority
- AR
- Argentina
- Prior art keywords
- gamma
- alfa
- lower alkyl
- lower alkoxy
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere a métodos de preparación de los compuestos, composiciones farmacéuticas que los contienen y su uso como medicamento para el tratamiento de la diabetes. Reivindicación 1: Compuestos de fórmula (1) en donde X es N e Y es S; o X es S e Y es N; R1 es arilo o heteroarilo; R2 es H, alquilo inferior o fluoro-alquilo inferior; R3, R4, R5 y R6 son independientemente uno del otro H, hidroxilo, alquenilo inferior, halógeno, alquilo inferior, fluoro-alquilo inferior, hidroxi-alquilo inferior, alcoxilo inferior-alquilo inferior, alcoxilo inferior, fluoro-alcoxilo inferior, hidroxi-alcoxilo inferior, alcoxilo inferior-alcoxilo inferior, en donde al menos uno de R3, R4, R5 y R6 no es H, o R3 y R4 están unidos uno al otro formando un anillo junto con los átomos de C a los que están unidos, y R3 y R4 juntos son -CH=CH-S-, -S-CH=CH-, -CH=CH-O-, -O-CH=CH-, -CH=CH-CH=CH, -(CH2)3-5, -O-(CH2)2-3- o -(CH2)2-3-O-, y R5 y R6 son tal como se han definido anteriormente; R7 es alquilo inferior, alcoxilo inferior, alqueniloxilo inferior, ariloxilo o aril-alcoxilo inferior; R8 es H o alquilo inferior; R9 y R10 independientemente uno del otro son H, alquilo inferior, alquenilo inferior, cicloalquilo, fenilo o [1,3]dioxan-2-etilo; n es 1, 2 o 3; y sales farmacéuticamente aceptables y/o ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02019146 | 2002-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041079A1 true AR041079A1 (es) | 2005-04-27 |
Family
ID=31970267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103120A AR041079A1 (es) | 2002-08-30 | 2003-08-28 | Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma) |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6809110B2 (es) |
| EP (1) | EP1537091B1 (es) |
| JP (2) | JP4533141B2 (es) |
| KR (1) | KR100736955B1 (es) |
| CN (1) | CN100475810C (es) |
| AR (1) | AR041079A1 (es) |
| AT (1) | ATE483699T1 (es) |
| BR (1) | BR0313946A (es) |
| CA (1) | CA2495942C (es) |
| DE (1) | DE60334461D1 (es) |
| DK (1) | DK1537091T3 (es) |
| ES (1) | ES2350340T3 (es) |
| GT (1) | GT200300183A (es) |
| HK (1) | HK1082504A1 (es) |
| HR (1) | HRP20050158A2 (es) |
| IL (1) | IL166833A (es) |
| MX (1) | MXPA05002115A (es) |
| MY (1) | MY141020A (es) |
| NO (1) | NO329777B1 (es) |
| NZ (1) | NZ537897A (es) |
| PA (1) | PA8581201A1 (es) |
| PE (1) | PE20040982A1 (es) |
| PL (1) | PL375779A1 (es) |
| PT (1) | PT1537091E (es) |
| RU (1) | RU2296754C2 (es) |
| SI (1) | SI1537091T1 (es) |
| TW (1) | TWI338686B (es) |
| UY (1) | UY27959A1 (es) |
| WO (1) | WO2004020420A1 (es) |
| ZA (1) | ZA200501097B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| CA2495942C (en) * | 2002-08-30 | 2010-03-23 | F. Hoffmann-La Roche Ag | Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists |
| GB0405033D0 (en) * | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| JP2009084156A (ja) * | 2006-01-18 | 2009-04-23 | Nissan Chem Ind Ltd | チアゾール置換アセトニトリルの製造方法 |
| JP2010520873A (ja) * | 2007-03-07 | 2010-06-17 | ドン・ア・ファーム・カンパニー・リミテッド | ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体、その方法およびそれを含む医薬組成物 |
| WO2008108602A1 (en) * | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| DE102007038251A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| CN101928259B (zh) * | 2009-06-18 | 2012-10-03 | 南京海辰药业有限公司 | 2-芳基噻唑衍生物及其药物组合物 |
| CN102285933B (zh) * | 2010-06-18 | 2016-03-09 | 浙江海正药业股份有限公司 | 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用 |
| CN102351852B (zh) * | 2011-08-23 | 2014-06-18 | 上海交通大学 | 苯并呋喃类化合物及其制备方法、用途 |
| EP2758041B1 (de) | 2011-09-20 | 2021-01-13 | Basf Se | Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung |
| EP3478297A1 (en) | 2016-06-30 | 2019-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
| CN111107902A (zh) * | 2017-03-14 | 2020-05-05 | 丹娜法伯癌症研究所 | Bax活化的用于诱导细胞死亡的小分子致敏 |
| WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
| CN115894379A (zh) * | 2022-01-20 | 2023-04-04 | 中国药科大学 | 海因类化合物及其医药用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011326A (en) * | 1975-07-29 | 1977-03-08 | Merck & Co., Inc. | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents |
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| RU2134686C1 (ru) * | 1992-07-03 | 1999-08-20 | Смитклайн Бичам П.Л.С. | Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии |
| GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
| DE4317320A1 (de) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| BR9713690B1 (pt) * | 1996-12-10 | 2009-08-11 | agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano. | |
| DE19711616A1 (de) * | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Verbessertes Verfahren zur Herstellung von Thiazolidindionen |
| US6121397A (en) * | 1997-07-14 | 2000-09-19 | Xerox Corporation | Polymerization processes using oligomeric compound, monomer and surfactant |
| HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| DE69815008T2 (de) | 1997-09-19 | 2004-04-01 | Ssp Co., Ltd. | Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel |
| AU1120599A (en) | 1998-04-23 | 1999-03-08 | Dr. Reddy's Research Foundation | New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DK1078923T3 (da) * | 1999-08-02 | 2006-07-10 | Hoffmann La Roche | Fremgangsmåde til fremstilling af benzothiophenderivater |
| JP2001261612A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| SK1872003A3 (en) * | 2000-08-23 | 2003-07-01 | Lilly Co Eli | Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists |
| KR100654516B1 (ko) * | 2001-05-15 | 2006-12-05 | 에프. 호프만-라 로슈 아게 | 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체 |
| DE60324898D1 (de) * | 2002-02-25 | 2009-01-08 | Lilly Co Eli | Modulatoren von peroxisome proliferator-aktivierten rezeptoren |
| CA2495942C (en) * | 2002-08-30 | 2010-03-23 | F. Hoffmann-La Roche Ag | Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists |
-
2003
- 2003-08-21 CA CA2495942A patent/CA2495942C/en not_active Expired - Fee Related
- 2003-08-21 KR KR1020057003571A patent/KR100736955B1/ko not_active IP Right Cessation
- 2003-08-21 CN CNB038205432A patent/CN100475810C/zh not_active Expired - Fee Related
- 2003-08-21 AT AT03757762T patent/ATE483699T1/de active
- 2003-08-21 EP EP03757762A patent/EP1537091B1/en not_active Expired - Lifetime
- 2003-08-21 DE DE60334461T patent/DE60334461D1/de not_active Expired - Lifetime
- 2003-08-21 BR BR0313946-8A patent/BR0313946A/pt not_active IP Right Cessation
- 2003-08-21 ES ES03757762T patent/ES2350340T3/es not_active Expired - Lifetime
- 2003-08-21 PT PT03757762T patent/PT1537091E/pt unknown
- 2003-08-21 WO PCT/EP2003/009281 patent/WO2004020420A1/en active IP Right Grant
- 2003-08-21 DK DK03757762.4T patent/DK1537091T3/da active
- 2003-08-21 MX MXPA05002115A patent/MXPA05002115A/es active IP Right Grant
- 2003-08-21 SI SI200331904T patent/SI1537091T1/sl unknown
- 2003-08-21 RU RU2005109163/04A patent/RU2296754C2/ru not_active IP Right Cessation
- 2003-08-21 PL PL03375779A patent/PL375779A1/xx not_active Application Discontinuation
- 2003-08-21 NZ NZ537897A patent/NZ537897A/en not_active IP Right Cessation
- 2003-08-21 JP JP2004532104A patent/JP4533141B2/ja not_active Expired - Fee Related
- 2003-08-26 TW TW092123445A patent/TWI338686B/zh not_active IP Right Cessation
- 2003-08-26 PA PA20038581201A patent/PA8581201A1/es unknown
- 2003-08-26 PE PE2003000873A patent/PE20040982A1/es not_active Application Discontinuation
- 2003-08-27 UY UY27959A patent/UY27959A1/es not_active Application Discontinuation
- 2003-08-27 GT GT200300183A patent/GT200300183A/es unknown
- 2003-08-28 AR ARP030103120A patent/AR041079A1/es active IP Right Grant
- 2003-08-28 MY MYPI20033266A patent/MY141020A/en unknown
- 2003-08-28 US US10/650,434 patent/US6809110B2/en not_active Expired - Fee Related
-
2005
- 2005-02-03 NO NO20050620A patent/NO329777B1/no not_active IP Right Cessation
- 2005-02-07 ZA ZA200501097A patent/ZA200501097B/en unknown
- 2005-02-10 IL IL166833A patent/IL166833A/en not_active IP Right Cessation
- 2005-02-18 HR HR20050158A patent/HRP20050158A2/xx not_active Application Discontinuation
-
2006
- 2006-04-03 HK HK06104073.6A patent/HK1082504A1/xx not_active IP Right Cessation
-
2010
- 2010-01-14 JP JP2010006072A patent/JP2010132671A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR041079A1 (es) | Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma) | |
| AR037983A1 (es) | Derivados de pirido [2,1-a] isoquinolina | |
| AR041997A1 (es) | Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR068695A2 (es) | Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa | |
| AR052549A1 (es) | Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2 | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR036778A1 (es) | Compuesto derivado de oxazolidinona sustituida y/o isoxazolina sustituida, profarmacos, su uso en la fabricacion de medicamentos, composicion farmaceutica y proceso para prepararlos | |
| AR049521A1 (es) | Derivados de pirrazol - pirimidina | |
| AR013085A1 (es) | Compuestos derivados de macrolidos c-4'' sustituidos, composicion farmaceutica, metodo de preparacion, compuestos intermediarios para su preparacion | |
| AR067904A1 (es) | Derivados de piperazina-amida | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| AR020851A2 (es) | Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |